Nuveen
AXSM icon

Nuveen’s Axsome Therapeutics AXSM Stock Holding History

Nuveen’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-86,500
Closed -$4K – 3184
2022
Q3 		$4K Buy
+86,500
New +$4.32M ﹤0.01% 3211

Other funds holding AXSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Nuveen's AXSM Position: Q3 2026 in Review

Nuveen increased its Axsome Therapeutics (AXSM) stake by 16% in Q3 2026, buying an estimated $6.42M and bringing the position to 219,600 shares worth $40.5M. The position accounts for 0.01% of the portfolio, ranked #806.

Nuveen first reported a position in AXSM in Q2 2019 and has held it in 30 quarters since. The position peaked at $63.8M in Q4 2025. 235 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Nuveen held 219,600 shares of Axsome Therapeutics worth $40.5M as of Q3 2026.
  • Nuveen bought 29,520 Axsome Therapeutics shares in Q3 2026, an estimated $6.42M.
  • Axsome Therapeutics made up 0.01% of Nuveen's portfolio in Q3 2026, its #806 holding.
  • Nuveen first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 30 quarters since.
  • Nuveen's Axsome Therapeutics position peaked at $63.8M in Q4 2025.
  • 235 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.